Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 979 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stability Clear all
Completed Not applicable Interventional Accepts healthy volunteers

AECOPD and Nutritional Supplementation in COPD

NCT06801964
View directory record Official record
Conditions
Obstructive Pulmonary Disease, Exacerbation Copd
Interventions
Stable isotope infusion, Protein and Fish Oil, Protein and Olive Oil, Carbohydrate and Olive Oil
Other · Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops

NCT05660681
View directory record Official record
Conditions
Dry Eye Disease
Interventions
glycerin 0.7%/PEG 400 0.3%, polyethylene glycol 400 0.4%/propylene glycol 0.3%
Drug
Lead sponsor
Calm Water Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 21, 2026, 5:34 AM EDT
Recruiting Phase 1 Interventional

A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

NCT07465653
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
HJB647 low dose, HJB647 high dose, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Bradenton, Florida • Inverness, Florida • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants

NCT04484857
View directory record Official record
Conditions
Anemia Associated With End Stage Renal Disease
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Anchorage, Alaska • Pine Bluff, Arkansas • Cerritos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 21, 2026, 5:34 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Quest to Analyze One Thousand Humans Meditating

NCT06583395
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions
Advanced multi-component meditation practice
Behavioral
Lead sponsor
Tobias Moeller-Bertram
Industry
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palm Desert, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV)

NCT01214200
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Bilevel positive airway pressure (BiPAP)
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
Up to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate the Effects of TRV120027 in Patients With Heart Failure

NCT01187836
View directory record Official record
Conditions
Heart Failure
Interventions
TRV120027, Placebo
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Serologically Active, Clinically Stable Systemic Lupus Erythematosus

NCT00000421
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Prednisone, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
13 Years to 65 Years · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
3
States / cities
New Hyde Park, New York • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults

NCT04614948
View directory record Official record
Conditions
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19
Interventions
Ad26.COV2.S, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
31,835 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
63
States / cities
Vestavia Hills, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Brief Behavioral Health Intervention Program for Patients With Stable Coronary Artery Disease

NCT03629158
View directory record Official record
Conditions
Coronary Artery Disease, Ischemic Heart Disease, Coronary Heart Disease
Interventions
CLIMB intervention
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
30 Years to 79 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg

NCT00918138
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Metformin XR, Placebo matching Metformin XR, Placebo matching Saxagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 78 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Phoenix, Arizona • Redlands, California • Tustin, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

NCT02273726
View directory record Official record
Conditions
CKD Anemia in Stable Dialysis Patients
Interventions
Epoetin Alfa, Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
74
States / cities
Phoenix, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 21, 2026, 5:34 AM EDT
Active, not recruiting Phase 3 Interventional

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

NCT06163326
View directory record Official record
Conditions
Vitiligo
Interventions
Ritlecitinib, Ritlecitinib 100 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
22
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure

NCT01251406
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Placebo, rhNRG-1 Dose 1, rhNRG-1 Dose 2
Drug
Lead sponsor
Zensun Sci. & Tech. Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • Tustin, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

Utility of Continuous Pulse Oximetry for Pediatric Patients With Stable Respiratory Illness

NCT04407806
View directory record Official record
Conditions
Respiratory Disease, Asthma in Children, Pneumonia in Children, Bronchiolitis Acute
Interventions
Continous Pulse oximeter, Intermittent Pulse oximeter
Device
Lead sponsor
Corewell Health East
Other
Eligibility
3 Months to 14 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects

NCT01952132
View directory record Official record
Conditions
Schizophrenia
Interventions
OMS643762, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263

NCT01128621
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients

NCT00282568
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Tacrolimus Modified Release (MR), tacrolimus
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients

NCT01270347
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
MP-376 (Levofloxacin Solution for Inhalation), TIS (Tobramycin Inhalation Solution)
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
99
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 21, 2026, 5:34 AM EDT
Completed No phase listed Observational

Work of Breathing and Kangaroo Mother Care

NCT03683316
View directory record Official record
Conditions
Premature Infant, Work of Breathing, Oxygen Saturation
Interventions
Not listed
Lead sponsor
Christiana Care Health Services
Other
Eligibility
4 Days to 6 Months
Enrollment
29 participants
Timeline
2018 – 2020
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 21, 2026, 5:34 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Lidocaine and Esmolol to Improve the Quality of Recovery

NCT01114997
View directory record Official record
Conditions
Pain, Constipation, Nausea, Vomiting
Interventions
Lidocaine, Esmolol, Lidocaine + Esmolol (Combo)
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 21, 2026, 5:34 AM EDT
Active, not recruiting Phase 3 Interventional

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183
View directory record Official record
Conditions
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Interventions
Ritlecitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
68
States / cities
Scottsdale, Arizona • Bryant, Arkansas • Fountain Valley, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy

NCT04164888
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
CIVI 007
Drug
Lead sponsor
Civi Biopharma, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Jacksonville, Florida • Port Orange, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 21, 2026, 5:34 AM EDT
Recruiting Phase 3 Interventional

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827
View directory record Official record
Conditions
Kidney Disease
Interventions
Mezagitamab, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
41
States / cities
Birmingham, Alabama • Montgomery, Alabama • Surprise, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 5:34 AM EDT